Abstract
Systemic antibiotics are the group of drugs most commonly used in children. Off-label antibiotic use in children is still common in the community and in hospitals, mostly because of young age, dosage, or frequency of drug application. There is an important incentive gap that hinders paediatric drug development resulting from a series of factors, such as small market size, a predominance of off-patent use, no incentives for generic drug manufacturers, and a greater complexity of drug development. The latter is due to varying capacities of drug absorption and metabolism during growth and maturation and the need for oral formulations in neonates and infants. High ethical barriers, combined with concerns of parents about drug safety, further complicate the conduct of clinical studies in children. While many off-patent antibiotics today are labelled for use in children, newer substances such as fluoroquinolones, azithromycin, linezolid, or daptomycin are not. This is of concern in the light of emerging multidrug-resistant pathogens.
Keywords: Antibiotic therapy, children, infants, neonates, off-label use, off-licensed, unlicensed, frequency of drug application, paediatric, adverse drug reaction
Current Drug Targets
Title:Antibiotic Use in Children - Off-Label Use
Volume: 13 Issue: 7
Author(s): Walter Zingg and Klara M. Posfay-Barbe
Affiliation:
Keywords: Antibiotic therapy, children, infants, neonates, off-label use, off-licensed, unlicensed, frequency of drug application, paediatric, adverse drug reaction
Abstract: Systemic antibiotics are the group of drugs most commonly used in children. Off-label antibiotic use in children is still common in the community and in hospitals, mostly because of young age, dosage, or frequency of drug application. There is an important incentive gap that hinders paediatric drug development resulting from a series of factors, such as small market size, a predominance of off-patent use, no incentives for generic drug manufacturers, and a greater complexity of drug development. The latter is due to varying capacities of drug absorption and metabolism during growth and maturation and the need for oral formulations in neonates and infants. High ethical barriers, combined with concerns of parents about drug safety, further complicate the conduct of clinical studies in children. While many off-patent antibiotics today are labelled for use in children, newer substances such as fluoroquinolones, azithromycin, linezolid, or daptomycin are not. This is of concern in the light of emerging multidrug-resistant pathogens.
Export Options
About this article
Cite this article as:
Zingg Walter and M. Posfay-Barbe Klara, Antibiotic Use in Children - Off-Label Use, Current Drug Targets 2012; 13 (7) . https://dx.doi.org/10.2174/138945012800675777
DOI https://dx.doi.org/10.2174/138945012800675777 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
New drug therapy for eye diseases
Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Insights into Airway Infections by Enterococci: A Review
Recent Patents on Anti-Infective Drug Discovery Natural Products Towards the Discovery of Potential Future Antithrombotic Drugs
Current Pharmaceutical Design Scintigraphic Imaging of Inflammatory Processes
Medicinal Chemistry Reviews - Online (Discontinued) Occurrence and Clinical Impact of Microembolic Signals (MES) in Patients with Chronic Cardiac Diseases and Atheroaortic Plaques - A Systematic Review
Current Vascular Pharmacology Epidemiology of Septic Acute Kidney Injury
Current Drug Targets Adenotonsillar Disease
Recent Patents on Inflammation & Allergy Drug Discovery Role of Old Antibiotics in Multidrug Resistant Bacterial Infections
Current Drug Targets Exploring the Biology and Structural Architecture of Sortase Role on Biofilm Formation in Gram Positive Pathogens
Current Topics in Medicinal Chemistry New Developments in Antimicrobial Use in Sepsis
Current Pharmaceutical Design Linezolid Activity Against Disseminated Listeria monocytogenes Meningitis and Central Nervous System Abscesses: Focus on Early Drug Myelotoxicity
Current Drug Safety Novel Perspective for Antithrombotic Therapy in TAVI
Current Pharmaceutical Design Comparative Time-Kill Study of Doxycycline, Tigecycline, Cefazolin and Vancomycin Against Several Clones of Staphylococcus aureus
Current Clinical Pharmacology Pneumonia Caused by Staphylococcus aureus
Current Respiratory Medicine Reviews Update on Childhood Brucellosis
Recent Patents on Anti-Infective Drug Discovery Cardiovascular Implantable Electronic Device Infections: Risk Scoring and Role of Antibiotic Envelope in Prevention
Recent Advances in Cardiovascular Drug Discovery (Discontinued) Anionic Antimicrobial Peptides from Eukaryotic Organisms and their Mechanisms of Action
Current Chemical Biology Cardiac Workup of Ischemic Stroke
Current Cardiology Reviews The Co-Metabolism within the Gut-Brain Metabolic Interaction: Potential Targets for Drug Treatment and Design
CNS & Neurological Disorders - Drug Targets Cocaine and Acute Vascular Diseases
Current Drug Abuse Reviews LC-MS for Simultaneous Determination of Vancomycin and Teicoplanin in Patient Plasma and its Application to Therapeutic Drug Monitoring
Current Pharmaceutical Analysis